Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)

Aclaris Therapeutics has reported Change in Receivables over the past 8 years, most recently at -$56000.0 for Q2 2025.

  • Quarterly results put Change in Receivables at -$56000.0 for Q2 2025, down 16.67% from a year ago — trailing twelve months through Jun 2025 was -$131000.0 (down 23.58% YoY), and the annual figure for FY2024 was $20000.0, up 110.75%.
  • Change in Receivables for Q2 2025 was -$56000.0 at Aclaris Therapeutics, up from -$68000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for ACRS hit a ceiling of $202000.0 in Q1 2023 and a floor of -$255000.0 in Q2 2023.
  • Median Change in Receivables over the past 5 years was -$44000.0 (2022), compared with a mean of -$32111.1.
  • Peak annual rise in Change in Receivables hit 1920.0% in 2023, while the deepest fall reached 6475.0% in 2023.
  • Aclaris Therapeutics' Change in Receivables stood at -$188000.0 in 2021, then skyrocketed by 39.89% to -$113000.0 in 2022, then surged by 57.52% to -$48000.0 in 2023, then surged by 47.92% to -$25000.0 in 2024, then tumbled by 124.0% to -$56000.0 in 2025.
  • The last three reported values for Change in Receivables were -$56000.0 (Q2 2025), -$68000.0 (Q1 2025), and -$25000.0 (Q4 2024) per Business Quant data.